CYX Calyx Ventures Inc

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) ("Calyx" or the "Company") is pleased
to announce that it has applied to the TSX Venture Exchange (the "Exchange") for
approval to the extension of the expiry date of up to 7,567,834 common share
purchase warrants (the "Warrants") issued to placees and finders as part of a
private placement financing which closed in two tranches on November 9, 2012 and
December 13, 2012. The expiry date of the Warrants issued on November 9, 2012
(the "First Tranche Warrants") is currently November 9, 2013 and the expiry date
of the Warrants issued on December 13, 2012 (the "Second Tranche Warrants") is
currently December 13, 2013. The Company is applying to extend the expiry dates
for the Warrants by 6 months, so that the First Tranche Warrants will expire on
May 9, 2014 and the Second Tranche Warrants will expire on June 13, 2014.


All other terms of the Warrants will remain the same. The warrant amendment
remains subject to the approval of the Exchange.


About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
focused on renewable fuels including biojet and biodiesel. Agrisoma Biosciences
Inc., a company in which Calyx is the largest shareholder, is producing a new
proprietary non-food energy feedstock crop, Resonance(R) carinata, which yields
oil that can be refined into fuels that work in existing engines as a 100
percent petroleum substitute. From seed to sky, fuels produced from Resonance(R)
carinata substantially reduce carbon and other harmful emissions, and help to
reduce global petroleum dependence. For further information about Calyx, please
visit www.calyxbio.com. Resonance(R) is a registered trademark of Agrisoma
Biosciences Inc. 


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control, including the completion of the
Private Placement and the delay or failure to receive regulatory approvals., 


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect. In addition to other assumptions
identified in this news release, assumptions have been made regarding, among
other things, timing and completion of the Private Placement, the actual use of
proceeds, and the timing of receipt of regulatory approvals. 


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604-649-5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From May 2024 to Jun 2024

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From Jun 2023 to Jun 2024